KLRC1 and B-cell chronic lymphocytic leukemia: NKG2A is overexpressed in NK cells from chronic lymphocytic leukemia patients, and blocking NKG2A with monalizumab is sufficient to restore the direct cytotoxicity of NK cells against HLA-E-expressing tumor cells (37).